All In Biotech

Drug Trial Radar · NCT07476326

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

A Randomized, Double-Blind, Parallel, Multicenter, Two-Arm Study to Compare the Pharmacokinetics, Safety, and Immunogenicity Between Bmab1700 and Opdivo® After Complete Resection of Stage IIB/C, Stage III, or Stage IV Melanoma

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Aug 16, 2027

Study completion Feb 16, 2028

Sponsor

Lead sponsor
Biocon Biologics UK PLCIndustry
Sponsor type
Industry
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.

Conditions

  • Melanoma

Interventions

  • Bmab1700Drug

    Intravenous infusion.

  • OpdivoDrug

    Intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve from Time 0 (Day 1) To Day 29 After the First Dose (AUC0-28days) of Bmab 1700 and OpdivoTime frame: Week 0 through Week 4
  2. Area Under the Concentration-Time Curve Over a Dosing Interval (AUC0-tau) of Bmab 1700 and OpdivoTime frame: Week 16 through Week 20

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • Biocon Investigational Site

    Bento Gonçalves, Brazil · Not yet recruiting

  • Biocon Investigational Site

    Ijuí, Brazil · Not yet recruiting

  • Biocon Investigational Site

    Pará, Brazil · Not yet recruiting

  • Biocon Investigational Site

    Porto Alegre, Brazil · Not yet recruiting

  • Biocon Investigational Site

    Rio de Janeiro, Brazil · Not yet recruiting

  • Biocon Investigational Site 1

    Santa Catarina, Brazil · Not yet recruiting

  • Biocon Investigational Site 2

    Santa Catarina, Brazil · Not yet recruiting

  • Biocon Investigational Site

    Santa Catarina, Brazil · Not yet recruiting

  • Biocon Investigational Site 1

    São Paulo, Brazil · Not yet recruiting

  • Biocon Investigational Site 2

    São Paulo, Brazil · Not yet recruiting

  • Biocon Investigational Site

    São Paulo, Brazil · Not yet recruiting

  • Biocon Investigational Site

    Providencia, Chile · Not yet recruiting

  • Biocon Investigational Site

    Recoleta, Chile · Not yet recruiting

  • Biocon Investigational Site 1

    Santiago, Chile · Not yet recruiting

  • Biocon Investigational Site

    Santiago, Chile · Not yet recruiting

  • Biocon Investigational Site

    Batumi, Georgia · Not yet recruiting

  • Biocon Investigational Site

    Kutaisi, Georgia · Not yet recruiting

  • Biocon Investigational Site 1

    Tbilisi, Georgia · Not yet recruiting

  • Biocon Investigational Site 3

    Tbilisi, Georgia · Not yet recruiting

  • Biocon Investigational Site 4

    Tbilisi, Georgia · Not yet recruiting

  • Biocon Investigational Site 5

    Tbilisi, Georgia · Not yet recruiting

  • Biocon Investigational Site

    Tbilisi, Georgia · Not yet recruiting

  • Biocon Investigational Site

    Chisinau, Moldova · Not yet recruiting

  • Biocon Investigational Site

    Bucharest, Romania · Not yet recruiting

  • Biocon Investigational Site

    Cluj-Napoca, Romania · Not yet recruiting

  • Biocon Investigational Site

    Craiova, Romania · Recruiting

  • Biocon Investigational Site 1

    Belgrade, Serbia · Recruiting

  • Biocon Investigational Site

    Belgrade, Serbia · Recruiting

  • Biocon Investigational Site

    Kamenitz, Serbia · Recruiting

  • Biocon Investigational Site

    Kragujevac, Serbia · Recruiting

  • Biocon Investigational Site

    Niš, Serbia · Recruiting

  • Biocon Investigational Site

    George, South Africa · Not yet recruiting

  • Biocon Investigational Site 1

    Johannesburg, South Africa · Not yet recruiting

  • Biocon Investigational Site

    Johannesburg, South Africa · Not yet recruiting

  • Biocon Investigational Site 1

    Barcelona, Spain · Not yet recruiting

  • Biocon Investigational Site

    Barcelona, Spain · Not yet recruiting

  • Biocon Investigational Site

    Madrid, Spain · Not yet recruiting

  • Biocon Investigational Site

    Murcia, Spain · Not yet recruiting

  • Biocon Investigational Site

    Sabadell, Spain · Not yet recruiting

  • Biocon Investigational Site 1

    Seville, Spain · Not yet recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.